DYN vs ENGN: fair value comparison
Dyne Therapeutics, Inc. and enGene Holdings Inc. · Updated 2026-10-19
DYN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ENGN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DYN currently ranks higher by quality score.
| DYN | ENGN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $14.25 | $1.67 |
| 12-month range | $14.25–$26.78 | $1.44–$12.17 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #236 of 301 Healthcare | #238 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: DYN fair value analysis · ENGN fair value analysis